The earnings beat was nice, but it didn’t calm any of the real worries. COVID sales keep shrinking, a bunch of their older dr-gs are creeping toward patent cliffs, and the pipeline feels more “maybe” than “solid plan.” Add in cost-cutting and pretty shaky market confidence, and it’s hard to know what we’re actually holding onto.
There are no replies in this thread yet. Be the first to post a reply below: